Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction

Clinical trial NCT06951841 · NOT_YET_RECRUITING

Trial details

NCT number: NCT06951841
Sponsor: China Medical University, China
Status: NOT_YET_RECRUITING
Phase: Phase 4
Study type: INTERVENTIONAL

Small Cell Lung Cancer

Start date: 2025-04-30
Primary completion: 2026-05-31
Enrollment: 31

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.